New York State Teachers Retirement System Sells 4,054 Shares of Jazz Pharmaceuticals PLC $JAZZ

by · The Markets Daily

New York State Teachers Retirement System reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 11.9% during the first quarter, HoldingsChannel.com reports. The firm owned 30,123 shares of the specialty pharmaceutical company’s stock after selling 4,054 shares during the quarter. New York State Teachers Retirement System’s holdings in Jazz Pharmaceuticals were worth $5,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Hilltop National Bank purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $38,000. Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $40,000. Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.5%

JAZZ opened at $247.72 on Wednesday. The stock has a market capitalization of $15.56 billion, a price-to-earnings ratio of -12,379.81, a PEG ratio of 0.21 and a beta of 0.32. The firm has a 50 day moving average price of $230.28 and a 200-day moving average price of $196.54. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $249.64. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the completion of the sale, the director owned 366,682 shares of the company’s stock, valued at $88,176,020.54. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 13,098 shares of company stock worth $3,131,906. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Piper Sandler lifted their target price on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, May 22nd. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Bank of America lifted their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.94.

Get Our Latest Stock Analysis on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Featured Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).